Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Cyclophosphamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,060Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Genentech’s Polivy Combo is New Standard for Untreated Lymphoma
    Genentech’s Polivy Combo is New Standard for Untreated Lymphoma

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241208818007/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    Fate Therapeutics Reports Q2 2024 Results And Business Updates
    Fate Therapeutics Reports Q2 2024 Results And Business Updates

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929617/24675/en/Fate-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Enforcement Report - Week of April 10, 2024
    Enforcement Report - Week of April 10, 2024

    10 Apr 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-10-2024-2074.pdf

    FDA
    10 Apr 2024
    Share Share
    Fresenius Kabi Further Expands Oncology Portfolio
    Fresenius Kabi Further Expands Oncology Portfolio

    28 Feb 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240228816982/en

    BUSINESSWIRE
    28 Feb 2024
    Share Share
    Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan
    Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan

    18 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/18/2811519/37414/en/Panbela-Announces-Publication-of-Clinical-Data-Titled-Phase-1-study-of-high-dose-DFMO-celecoxib-cyclophosphamide-and-topotecan-for-patients-with-relapsed-neuroblastoma-A-New-Approa.html

    GLOBENEWSWIRE
    18 Jan 2024
    Share Share
    RK Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.
    RK Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.

    18 Dec 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216958

    FDA
    18 Dec 2023
    Share Share